A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
E. A. Troshina,
M. B. Antsiferov,
A. S. Ametov,
G. R. Galstyan,
T. N. Markova,
T. I. Romantsova,
N. V. Mazurina,
O. M. Koteshkova https://doi.org/10.14341/probl13677
Abstract
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.
About the Authors
E. A. Troshina
Endocrinology Research Centre
Russian Federation
Russian Federation
Ekaterina A. Troshina, MD, PhD, Professor
Moscow, st. Dmitry Ulyanov 11, 117292
M. B. Antsiferov
Endocrinological Dispensary
Russian Federation
Russian Federation
Mikhail B. Antsiferov, MD, PhD
Moscow
A. S. Ametov
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Alexander S. Ametov, MD, PhD, Professor
Moscow
G. R. Galstyan
Endocrinology Research Centre
Russian Federation
Russian Federation
Gagik R. Galstyan, MD, PhD, Professor
Moscow
T. N. Markova
Russian University of Medicine
Russian Federation
Russian Federation
Tatiana N. Markova
Moscow
T. I. Romantsova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Tatiana I. Romantsova, MD, PhD, Professor
Moscow
N. V. Mazurina
Endocrinology Research Centre
Russian Federation
Russian Federation
Natalya V. Mazurina, MD. PhD
Moscow
O. M. Koteshkova
Endocrinological Dispensary
Russian Federation
Russian Federation
Olga M. Koteshkova, MD, PhD
Moscow
References
1. McGowan B, Ciudin A, Baker JL, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025. doi: https://doi.org/10.1038/s41591-025-03765-w
2. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23 Suppl 3:5-29. doi: https://doi.org/10.1111/dom.14496
3. Christel CM, DeNardo DF, Secor SM. Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum). J Exp Biol. 2007;210(Pt 19):3430-9. doi: https://doi.org/10.1242/jeb.004820
4. Park JS, Kim KS, Choi HJ. Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies. Diabetes Metab J. 2025;49(3):333-347. doi: https://doi.org/10.4093/dmj.2025.0106
5. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-5
6. Krook A, Mulder H. Incretins: turning the venom into the antidote. Diabetologia. 2023;66(10):1762-1764. doi: https://doi.org/10.1007/s00125-023-05987-4
7. De Graaf C, Donnelly D, Wootten D, et al. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol. Rev. 2016;68:954–1013. doi: https://doi.org/10.1124/pr.115.011395
8. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18:3-14. doi: https://doi.org/10.1016/j.molmet.2018.09.009
9. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. doi: https://doi.org/10.1172/jci.insight.140532
10. Романцова Т.И. Тирзепатид — унимолекулярная полифармакология для лечения ожирения. // Эндокринология: новости, мнения, обучение. — 2025. — Т.14. — № 3. — C. 50-64. doi: https://doi.org/10.33029/2304-9529-2025-14-3-50-64
11. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi: https://doi.org/10.1016/j.molmet.2019.09.010
12. Müller TD, Adriaenssens A, Ahrén B, et al. Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 2025;95:102118. doi: 10.1016/j.molmet.2025.102118
13. Campbell JE, Müller TD, Finan B, et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 2023;35(9):1519-1529. doi: https://doi.org/10.1016/j.cmet.2023.07.010
14. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. doi: https://doi.org/10.1172/jci.insight.133429
15. Samms RJ, Sloop KW. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes. 2025: dbi240026. doi: https://doi.org/10.2337/dbi24-0026
16. Boer GA, Hay DL, Tups A. Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol Sci. 2023;44(1):50-63. doi: https://doi.org/10.1016/j.tips.2022.11.001
17. O’Keefe JH, Franco WG, O’Keefe EL. Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Prog Cardiovasc Dis. 2025;89:102-112. doi: https://doi.org/10.1016/j.pcad.2024.12.010
18. James-Okoro PP, Lewis JE, Gribble FM, Reimann F. The role of GIPR in food intake control. Front Endocrinol (Lausanne). 2025;16:1532076. doi: https://doi.org/10.3389/fendo.2025.1532076
19. Douros JD, Flak JN, Knerr PJ. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP. Front Endocrinol (Lausanne). 2025;16:1530985. doi: https://doi.org/10.3389/fendo.2025.1530985
20. Samms RJ, Cosgrove R, Snider BM, et al. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior. Diabetes. 2022;71(7):1410-1423. doi: https://doi.org/10.2337/db21-0848
21. Urva S, Coskun T, Loghin C, et al. The novel dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. doi: https://doi.org/10.1111/dom.14110
22. Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1-15. doi: https://doi.org/10.1210/clinem/dgae719. Erratum in: J Clin Endocrinol Metab. 2025;110(10):e3556. doi: https://doi.org/10.1210/clinem/dgaf387
23. Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Des Devel Ther. 2025;19:3509-3537. doi: https://doi.org/10.2147/DDDT.S506957
24. Wong CK, McLean BA, Baggio LL, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonistinduced inflammation. Cell Metab. 2024;36(1):130-143.e5. doi: https://doi.org/10.1016/j.cmet.2023.11.009
25. Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):14514-14541. doi: https://doi.org/10.3390/cimb46120872
26. Regmi A, Aihara E, Christe ME, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024;36(7):1534-1549.e7. doi: https://doi.org/10.1016/j.cmet.2024.05.010
27. Yu X, Chen S, Funcke JB, et al. The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. Cell Metab. 2025;37(1):187-204.e7. doi: https://doi.org/10.1016/j.cmet.2024.11.003
28. Yaribeygi H, Maleki M, Jamialahmadi T, Sahebkar A. Anti-inflammatory benefits of semaglutide: State of the art. J Clin Transl Endocrinol. 2024;36:100340. doi: https://doi.org/10.1016/j.jcte.2024.100340
29. Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15-28. doi: https://doi.org/10.1016/S2213-8587(24)00271-7
30. Vear A, Heneka MT, Clemmensen C. Incretin-based therapeutics for the treatment of neurodegenerative diseases. Nat Metab. 2025;7(4):679-696. doi: https://doi.org/10.1038/s42255-025-01263-4
31. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, et al; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. doi: https://doi.org/10.1056/NEJMoa2404881. Erratum in: N Engl J Med. 2024;391(15):1464. doi: https://doi.org/10.1056/NEJMx240005
32. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients With Obesity. Endocr Pract. 2016;22Suppl 3:1-203. doi: https://doi.org/10.4158/EP161365
33. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. doi: https://doi.org/10.1056/NEJMoa2416394
34. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: https://doi.org/10.1056/NEJMoa2307563
35. Zhao Z, Song J, Faurby M, et al. Lower Risk of MACE and All-Cause Death in Patients Initiated on Semaglutide 2.4 mg in Routine Clinical Care: Results from the SCORE Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Moderated poster presentation presented at the American College of Cardiology Scientific Session & Expo 2025; 29-31 March 2025; McCormick Place Convention Center, Chicago, US. Presentation 947-13
36. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, et al; SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi: https://doi.org/10.1056/NEJMoa2410027
37. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi: https://doi.org/10.1056/NEJMoa2306963
38. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, et al; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. doi: https://doi.org/10.1056/NEJMoa2404881. Erratum in: N Engl J Med. 2024;391(15):1464. doi: https://doi.org/10.1056/NEJMx240005
39. Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, et al; STEP 9 Study Group. OnceWeekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. doi: https://doi.org/10.1056/NEJMoa2403664
40. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, et al; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. doi: https://doi.org/10.1056/NEJMoa2401943
41. Phase 3 ESSENCE Trial: Semaglutide in Metabolic DysfunctionAssociated Steatohepatitis. Gastroenterol Hepatol (N Y). 2024;20(12 Suppl 11):6-7
42. McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietiläinen KH, et al; STEP 10 Study Group. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631-642. doi: https://doi.org/10.1016/S2213-8587(24)00182-7
43. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, et al; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. doi: https://doi.org/10.1056/NEJMoa2410819
44. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi: https://doi.org/10.1016/S0140-6736(23)01200-X
45. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebocontrolled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi: https://doi.org/10.1016/S0140-6736(21)00213-0
Review
For citations:
Troshina E.A., Antsiferov M.B., Ametov A.S., Galstyan G.R., Markova T.N., Romantsova T.I., Mazurina N.V., Koteshkova O.M. A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide. Problems of Endocrinology. 2025;71(5):19-30. (In Russ.) https://doi.org/10.14341/probl13677
Views:
50
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
